Quantitative measurements of alternating finger tapping in Parkinson's disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation

Tavares, Ana Lisa Taylor; Jefferis, Gregory S.X.E.; Koop, Mandy Miller; Hill, Bruce C.; Hastie, Trevor; Heit, Gary; Brontë‐Stewart, Helen

doi:10.1002/mds.20556

Cited by 173 publications

(127 citation statements)

References 47 publications

Supporting

Mentioning

119

Contrasting

Order By: Relevance

“…Although previous studies have tried to quantify the bradykinesia, they have neglected to consider multiple aspects of the bradykinesia [6][7][8][9][10][11]. Furthermore, they have investigated only single joint for quantification.…”

Section: Validation Of the Regression Modelsmentioning

confidence: 99%

“…Recently, there have been studies quantifying the bradykinesia using a musical instrument digital interface keyboard [6], joystick [7], accelerometer [8], magnetic sensor [9,10] and gyro sensor [11]. Various variables to represent the characteristics of bradykinesia were derived from the measured signals.…”

Section: Introductionmentioning

confidence: 99%

“…The consistency of the relationship between each characteristic variable and the clinical score (i.e. UPDRS bradykinesia score) [6,7,11] and the ability of each variable to discriminate different clinical scores [10,11] were evaluated in order to assess how well each variable denote the bradykinesia-specific features. A single characteristic variable may not fully include multiple aspects of bradykinesia such as speed, amplitude, hesitations, fatiguing, and arrests, while clinicians rate a single severity score from the observation and integration of multiple aspects of bradykinesia.…”

Section: Introductionmentioning

confidence: 99%

“…So far, there has been no study where the regression model was used to quantify bradykinesia. In the previous studies, many characteristic variables were shown to be significantly correlated with the clinical score [6,7,11]. When multiple variables are correlated with the clinical score, we need to know the relative importance of each variable on clinical rating of the bradykinesia.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Regression models for the quantification of Parkinsonian bradykinesia

Kim

Kwon

Yun

et al. 2015

BME

View full text Add to dashboard Cite

Abstract. The aim of this study was to develop regression models for the quantification of parkinsonian bradykinesia. Forty patients with Parkinson's disease participated in this study. Angular velocity was measured using gyro sensor during finger tapping, forearm-rotation, and toe tapping tasks and the severity of bradykinesia was rated by two independent neurologists. Various characteristic variables were derived from the sensor signal. Stepwise multiple linear regression analysis was performed to develop models predicting the bradykinesia score with the characteristic variables as input. To evaluate the ability of the regression models to discriminate different bradykinesia scores, ANOVA and post hoc test were performed. Major determinants of the bradykinesia score differed among clinical tasks and between raters. The regression models were better than any single characteristic variable in terms of the ability to differentiate bradykinesia scores. Specifically, the regression models could differentiate all pairs of the bradykinesia scores (p<0.05) except for one pair in the finger tapping task and one pair in the toe tapping task. In contrast, any single characteristic variable was found not sensitive enough to discriminate many of the pairs, especially in case of the toe tapping task. The results suggest that the multiple regression models reflecting these differences would be beneficial for the quantification of bradykinesia because the cardinal features included in the determination of bradykinesia score differ among tasks as well as among the raters.

show abstract

Section: Validation Of the Regression Modelsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Regression models for the quantification of Parkinsonian bradykinesia

Kim

Kwon

Yun

et al. 2015

BME

View full text Add to dashboard Cite

show abstract

“…Finger-tapping frequency inversely correlates with MDS-UPDRS-III motor subscale score when adjusted for age [21-23]. …”

Section: Methodsmentioning

confidence: 99%

Evaluation of D<sub>1</sub>/D<sub>5</sub> Partial Agonist PF-06412562 in Parkinson’s Disease following Oral Administration

et al. 2018

View full text Add to dashboard Cite

Background: PF-06412562 is a moderately potent, highly selective oral D₁/D₅ dopamine receptor partial agonist. Objective: To study the efficacy and safety of a single, oral, split dose of PF-06412562 in patients with Parkinson’s disease. Methods: Following overnight levodopa (L-dopa, Sinemet®) washout, subjects received a single dose of levodopa in open-label period 1. Periods 2 and 3 had a double-blinded, sponsor-open, randomized, 2-way cross-over, placebo-controlled design, during which subjects were randomized to PF-06412562 30 mg (+ 20 mg 4 h later) or placebo. Maximum percent improvement from baseline in finger-tapping speed (measure of bradykinesia) measured using Kinesia^TM technology (as the primary end point) and change from baseline in the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale Part III (MDS-UPDRS-III) motor section scores (the preferred exploratory end point) were evaluated. Results: Nineteen subjects received levodopa; 13 met the period 2/3 entry criteria and received PF-06412562, 30 + 20 mg, or placebo. The prespecified primary efficacy criterion for significant improvement in finger-tapping was not met due to inconsistencies in the task leading to large between-period fluctuations of within-patient baseline values. Change from baseline in MDS-UPDRS-III score with PF-06412562 resulted in a placebo-adjusted point estimate of –10.59 with a one-sided 90% upper CI of PF-06412562 versus placebo model-based contrast of (–inf, –7.44) at 1.5–2.5 h after the dose (p < 0.0001). All adverse events were mild-to-moderate. Conclusions: We report the first evidence of potential anti-parkinsonian efficacy of the oral selective D₁/D₅ partial agonist PF-06412562 without the significant acute changes in cardiovascular parameters reported with previous D₁ agonists.

show abstract

Omega-3 fatty acids for depression in adults

Appleton

Sallis

Perry

et al. 2015

Cochrane Database of Systematic Reviews

117

View full text Add to dashboard Cite

At present, we do not have sufficient high quality evidence to determine the effects of n-3PUFAs as a treatment for MDD. Our primary analyses suggest a small-to-modest, non-clinically beneficial effect of n-3PUFAs on depressive symptomology compared to placebo; however the estimate is imprecise, and we judged the quality of the evidence on which this result is based to be low/very low. Sensitivity analyses, funnel plot inspection and comparison of our results with those of large well-conducted trials also suggest that this effect estimate is likely to be biased towards a positive finding for n-3PUFAs, and that the true effect is likely to be smaller. Our data, however, also suggest similar rates of adverse events and numbers failing to complete trials in n-3PUFA and placebo groups, but again our estimates are very imprecise. The one study that directly compares n-3PUFAs and antidepressants in our review finds comparable benefit. More evidence, and more complete evidence, are required, particularly regarding both the potential positive and negative effects of n-3PUFAs for MDD.

show abstract

Quantitative measurements of alternating finger tapping in Parkinson's disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation

Cited by 173 publications

References 47 publications

Regression models for the quantification of Parkinsonian bradykinesia

Regression models for the quantification of Parkinsonian bradykinesia

Evaluation of D<sub>1</sub>/D<sub>5</sub> Partial Agonist PF-06412562 in Parkinson’s Disease following Oral Administration

Omega-3 fatty acids for depression in adults

Contact Info

Product

Resources

About